Cellect Biotechnology (NASDAQ:APOP) reported quarterly losses of $(0.00) per share. This is a 42.86 percent increase over losses of $(0.01) per share from the same period last year.
UBS Upgrades DTE Energy to Buy, Lowers Price Target to $127
UBS analyst Daniel Ford upgrades DTE Energy (NYSE:DTE) from Neutral to Buy and lowers the price target from $144 to $127.